Skip to main content
Clinical Trials/ITMCTR1900002748
ITMCTR1900002748
Not yet recruiting
Phase 1

A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer

Dongfang Hospital Beijing University of Chinese Medicine0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Dongfang Hospital Beijing University of Chinese Medicine
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Dongfang Hospital Beijing University of Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • (1\) Patients with histologically or cytologically confirmed NSCLC, and clinical stage IIIb or IV.
  • (2\) One of above five TCM syndrome pattern differentiation;
  • (3\) There is at least one lesion larger than 2cm in diameter that can be cryoablation in the lung;
  • (4\) The Eastern Cooperative Oncology Group (ECOG) score \<\= 2 and the expected survival time was more than 3 months
  • (5\) Aged more than 18 years;
  • (6\) Able to read Chinese and willingness to provide signed informed consent.

Exclusion Criteria

  • (1\) Patients who had received any radiation, chemotherapy, targeted therapy or immunotherapy for their cancers within a month;
  • (2\) Patients with symptomatic brain metastases;
  • (3\) Patients with infectious and radioactive inflammation around the lesion, or skin infection and ulceration at the puncture site;
  • (4\) Patients with severe pulmonary fibrosis especially drug\-induced pulmonary fibrosis;
  • (5\) Patients with severe bleeding tendency, platelet less than 50×109/L and severe coagulation disorders;
  • (6\) Patients with poor control of ipsilateral malignant pleural effusion;
  • (7\) Pregnant and lactating women; or severe insufficiency of liver, kidney, heart, lung and brain; or severe anemia, dehydration and serious disorders of nutrition metabolism, unable to be corrected or improved in a short time; or patients with severe systemic infection and high fever (T \> 38\.5 degree C).
  • (8\) HIV antibody positive or with other acquired or congenital immunodeficiency diseases;
  • (9\) Patients with a history of organ transplantation;
  • (10\) Patients enrolled in other clinical trials within three months.

Outcomes

Primary Outcomes

Not specified

Similar Trials